CJC-1295 DAC
Direct human data is limited to early pharmacology trials; recent literature focuses on the broader GHRH-analog class.
Therapeutic potential of growth hormone-releasing hormone analogues in cardiovascular and cerebrovascular diseases
This review summarised preclinical evidence that synthetic GHRH agonist analogues exert protective effects in animal models of myocardial infarction, heart failure and ischemic stroke, describing mechanisms reported to operate independently of GH/IGF-1 signalling.
View study ↗Growth hormone-releasing hormone receptor (GHRH-R) and its signaling
The authors described the structure, splice variants and signalling pathways of the GHRH receptor across normal and tumour tissues, framing how GHRH analogues engage this class-B GPCR.
View study ↗The development of growth hormone-releasing hormone analogs: advances in cancer, regenerative medicine, and metabolic disorders
This review by the group that developed many GHRH analogues catalogued the agonist and antagonist analogue series and surveyed preclinical findings reported across oncology, regenerative medicine and metabolic-disorder models.
View study ↗Growth hormone-releasing hormone and its analogues in health and disease
This comprehensive review described the biological activities of GHRH and its agonist and antagonist analogues, summarising reported roles in cell growth, wound healing, inflammation, metabolism and cardiovascular and neurodegenerative disease models.
View study ↗Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
In two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults, the authors reported that single subcutaneous doses of CJC-1295 produced dose-dependent increases in plasma GH and IGF-I lasting several days, with no serious adverse reactions reported.
View study ↗Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse
In this rodent study, the authors reported that once-daily administration of CJC-1295 to GHRH-knockout mice over five weeks restored body weight and length toward normal, with diminishing effects at longer dosing intervals.
View study ↗Provided for educational and reference purposes only. These materials are sold strictly for laboratory research and are not for human or animal use.